Biotech - Spark Newswire

1 minute read

Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle

Today, 6:14 AM

Cytokinetics Incorporated (NASDAQ:CYTK) presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). At…

CYTK

1 minute read

Esperion Long Term Data On Cholesterol Medication’s Ability To Cut Cardiovascular Risk Fails To Impress Investors

By Vandana Singh

Today, 6:14 AM

Esperion Therapeutics Inc (NASDAQ:ESPR) announced the full results from the CLEAR Outcomes trial, a global study of nearly 14,000 patients with…

ESPR

1 minute read

Immuneering Will Be Presenting Preclinical Data On Its Lead Program IMM-1-104 At American Association For Cancer Research Showing Broad Response Demonstrated Through Deep Cyclic Inhibition Of MAPK Pathway, Independent Of Specific RAS Mutation

By Benzinga Newsdesk

Today, 6:14 AM

Phase 1/2a clinical trial with IMM-1-104 is underway in patients with advanced solid tumors harboring RAS mutations.

IMRX

1 minute read

FDA Accepted Eisai-Biogen’s Supplemental Biologics License Application For Leqembi (Lecanemab-IRMB) 100 mg/ml Injection For Intravenous Use, Supporting The Conversion Of The Accelerated Approval Of Leqembi To A Traditional Approval

By Benzinga Newsdesk

Today, 6:14 AM

The LEQEMBI application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023. The FDA is currently planning to hold an Advisory Committee to discuss this application

BIIB

5 minute read

U.S. FDA Broadens Indication For Verzenio In HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

By Happy Mohamed

Today, 6:14 AM

High risk patients eligible for Verzenio can now be identified solely based on nodal status, tumor size, and tumor grade, regardless of Ki-67 score Approval supported by four-year data

LLY

1 minute read

Analyst Upgrades This Stock And Doubles Price Target On Encouraging Ibsrela Story

By Vandana Singh

Today, 6:14 AM

After the market close Thursday, Ardelyx Inc (NASDAQ:ARDX) reported Q4 FY22 Ibsrela sales of $8.7 million and $15.6 million for FY22. The…

ARDX

1 minute read

How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising

By Vandana Singh

Today, 6:14 AM

The U.S. government invested at least $31.9 billion to develop, produce, and purchase mRNA COVID-19 vaccines, including sizeable…

BNTX

1 minute read

Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo

By Vandana Singh

Today, 6:14 AM

Exelixis Inc (NASDAQ:EXEL) announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS). CONTACT-03 is…

EXEL

1 minute read

Why Veru Stock Is Crashing Today?

By Vandana Singh

Today, 6:14 AM

The FDA declined to grant Veru Inc’s (NASDAQ:VERU) request for Emergency Use Authorization (EUA) for sabizabulin to treat hospitalized adult patients…

VERU

1 minute read

Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study

By Vandana Singh

Today, 6:14 AM

Praxis Precision Medicines Inc (NASDAQ:PRAX) announced topline results from the Essential1 study evaluating the efficacy, safety, and tolerability of ulixacaltamide (PRAX-944)…

PRAX